LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Edgewise Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKEREWTX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / EWTX COVERAGE

What’s moving Edgewise Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?

Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?

Investors are testing whether Edgewise Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

The development tests whether Edgewise Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
03
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

The story matters when it changes Edgewise Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

The story matters when it changes Edgewise Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest EWTX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-K/AMaterial company eventFiled 2026-07-16 · Period 2026-07-10SEC ↗8-KMaterial company eventFiled 2026-07-13 · Period 2026-07-10SEC ↗8-KMaterial company eventFiled 2026-06-05 · Period 2026-06-04SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-23 · Period 2026-06-04SEC ↗4Official SEC filingFiled 2026-07-17 · Period 2026-06-05SEC ↗
EARNINGS / QUARTERLY TRACKER

Edgewise Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.